This Good Practice Paper was compiled according to the British Society for Haematology (BSH) process at www.b-s-h.org.uk. The BSH produces Good Practice Papers to recommend good practice in areas where there is a limited evidence base but for which a degree of consensus or uniformity is likely to be beneficial to patient care.
Introduction
The guidance for the investigation and management of mantle cell lymphoma (MCL), published in 2012 (McKay, et al 2012) , has been updated and divided into two papers -this Good Practice Paper incorporating new information on pathology, in particular molecular pathology, and use of positron emission tomography/computed tomography (PET/CT) Author's final draft of a paper accepted for publication in British Journal of Haematology 2018 DOI 10.1111/bjh.15281. scanning in staging and response assessment and a Guideline on the Management of MCL including new therapeutic options and transplant data (McKay et al 2018) .
MCL is a B cell malignancy with unique biological, pathological and clinical features, comprising 3-10% of all non-Hodgkin lymphomas (NHLs) (Swerdlow, et al 1983) . It was recognised as a specific entity in the revised European-American classification of lymphoid neoplasms (REAL) classification (Harris, et al 1994) and is characterized by the chromosomal translocation t(11;14)(q13.3;q32.33), which results in overexpression of the cell cycle protein cyclin D1 (Akiyama, et al 1994 , Campo, et al 1999 .
MCL arises mainly in older adults (median age of presentation is 60-65 years) and has a male predominance (Argatoff, et al 1997 , Bosch, et al 1998 . It often has the worst features of both high-and low-grade NHL; an aggressive clinical course, but with a pattern of resistant and relapsing disease, rendering it incurable with standard therapy. Historically, the median survival was 4-5 years (Herrmann, et al 2009) however this is now in the order of 8-12 years in younger fitter patients who are able to tolerate modern intensive therapies (Eskelund, et al 2016 .
A number of studies have described the clinical presentation of MCL (Argatoff, et al 1997 , Bosch, et al 1998 , Tiemann, et al 2005 , Zucca, et al 1995 . The majority (>90%) of patients present with advanced stage (Ann Arbor III-IV) disease. Lymphadenopathy is generally widespread at diagnosis, and splenomegaly, bone marrow infiltration and peripheral blood involvement are common. Bulk disease at diagnosis and B symptoms are less common. Extra nodal involvement is frequent, particularly affecting the gastro-intestinal tract (Romaguera, et al 2003) and liver, but infiltration of breast, lung, skin, soft tissue, salivary gland and orbit are also seen. Involvement of more than 2 extra nodal sites is seen in 30-50% of patients (Jares and Campo 2008) . Spread to the central nervous system (CNS) can occur (see below) but is rare at diagnosis.
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The clinical course of MCL is heterogeneous. Clinical presentation can correlate with pathological sub-type; notably patients with blastoid histology tend to have an aggressive clinical course, show refractoriness to treatment and have short survival. In contrast, a proportion of cases may present with more indolent disease (Eve, et al 2009 , Martin, et al 2009 , characterized by splenomegaly, peripheral blood lymphocytosis, and little or no nodal disease (Nodit, et al 2003 , Orchard, et al 2003 . Survival in this group is of the order of 5-12 years. Furthermore, the entity of MCL in situ is now recognized, indicating early foci of disease in otherwise reactive nodes in asymptomatic patients (Carvajal-Cuenca, et al 2012) .
Outside these extremes, the heterogeneity of the disease and the age of patients in which it presents, frequently necessitate an individualized approach.
CNS disease
Three recent publications (Cheah, et al 2013 , Chihara, et al 2015 , Conconi, et al 2013 have reported a CNS relapse rate between 4.1 and 7.8% with high Ki67 and blastoid histology identified as risk factors in multivariate analysis. CNS relapse tends to occur early (median of 15 to 20 months) and survival is poor (3 to 8 months). A high incidence of leptomeningeal disease (91% by flow cytometry) has been reported (Cheah, et al 2013) with parenchymal disease being uncommon (12% of cases).
Diagnosis
Morphology: the diagnosis of MCL may be made by an excision or adequate core biopsy of an involved site, endoscopic biopsy, bone marrow trephine biopsy or peripheral blood specimen in cases with a leukaemic presentation.
In the classical variant (87% of cases), the architecture of the involved lymph node is usually completely effaced and is replaced by a diffuse or, less commonly, a nodular infiltrate composed of a monomorphic population of small to intermediate sized cells with irregular, often cleaved nuclei resembling centrocytes (Argatoff, et al 1997 , Swerdlow, et al 1983 , Tiemann, et al 2005 . A mantle zone pattern is seen in a minority of cases (Tiemann, et al 2005) . Vascular hyalinization is often conspicuous and there may also be prominent scattered epithelioid histiocytes, especially in cases with a higher proliferation fraction. A small cell variant (3.6% of cases) resembling small lymphocytic lymphoma, though lacking proliferation centres, is recognized. Other subtypes include the blastoid variant (2.6%), morphologically resembling lymphoblastic lymphoma and the pleomorphic variant (5.9%), which may be confused on morphological grounds with diffuse large B cell lymphoma (DLBCL) (Argatoff, et al 1997 , Norton, et al 1995 , Ott, et al 1997 , Swerdlow, et al 1983 , Tiemann, et al 2005 . Cases with more than one variant pattern may also occur (Tiemann, et al 2005) . Identical cytomorphological features are identified in biopsies of extranodal sites. In trephine biopsy specimens, the infiltrate is most commonly nodular and interstitial and less often paratrabecular or diffuse (Argatoff, et al 1997 , Cohen, et al 1998 .
Immunophenotype [formalin-fixed paraffin-embedded (FFPE) tissue]: the majority of MCL cases co-express CD20, CD5, BCL2, cyclin D1 and SOX11 and are usually negative for CD10, BCL6 and CD23 (Alkan, et al 1995 , Argatoff, et al 1997 , Sander, et al 2007 , Soldini, et al 2014 , Swerdlow, et al 1995 . CD21 highlights a diffuse disorganized network of follicular dendritic cells though this may be variable in extent. With modern antibodies to cyclin D1 (SP4 clone) nuclear expression of cyclin D1 is seen in the great majority of cases (Alkan, et al 1995 , Swerdlow, et al 1995 and false negativity is usually related to poor fixation or inadequate antigen retrieval (Fu, et al 2005) . In cases with equivocal staining, immunohistochemistry (IHC) for the neuronal transcription factor SOX11 and fluorescence in situ hybridization (FISH) for IGH/CCND1 should be added (Dictor, et al 2009 , Ek, et al 2008 , Remstein, et al 2000 , Sander, et al 2007 , Soldini, et al 2014 . An aberrant Author's final draft of a paper accepted for publication in British Journal of Haematology 2018 DOI 10.1111/bjh.15281.
immunophenotype, such as CD5 negativity or expression of CD10, BCL6 or CD23, occurs in 5-18% of cases and may lead to an erroneous diagnosis (Camacho, et al 2004 , Espinet, et al 2010 , Gualco, et al 2010 , Schlette, et al 2003 , Wlodarska, et al 1999 , Zanetto, et al 2008 , Flow Cytometry (peripheral blood or bone marrow): typically, MCL expresses CD19, CD20, CD79b, CD22, CD5 and FMC7 with moderately intense expression of surface light chains, more commonly lambda (Bertoni, et al 1999) . CD10 expression is seen in a small proportion of cases, particularly in those with blastoid morphology (Zanetto, et al 2008) . Although cyclin D1 expression cannot be assessed by flow cytometry, SOX11 expression is detectable and may assist in distinguishing CLL from MCL on peripheral blood samples (Wasik, et al 2015) .
Lack of expression of CD200 in MCL in contrast to CLL (Spacek 2014 ) may also discriminate between these entities.
Cyclin D1-negative MCL
Genuine cyclin D1-negative cases of MCL lacking the IGH/CCND1 rearrangement have been recognized through gene expression profiling and are rare (Fu, et al 2005 , Herens, et al 2008 , Quintanilla-Martinez, et al 2009 . The cytomorphology, immunophenotype (other than cyclin D1 negativity) and clinical course are identical to cases of classical MCL. The lymphoma is characterized by a rearrangement of CCND2 in 55% of cases (Salaverria, et al 2013) . Some cases involve CCND3. SOX11 is expressed within the nucleus of almost all cyclin D1-negative cases enabling this entity to be reliably identified (Carvajal-Cuenca, et al 2012 , Ek, et al 2008 , Mozos, et al 2009 . Immunocytochemistry for SOX11 should be added in all cases of CD5-positive/cyclin D1-negative B-cell lymphoma.
In situ MCL
This rare entity is characterised by the presence of CD5+ cyclinD1+ small lymphocytes in the mantle zone of the follicle in a morphologically reactive lymph node (Richard, et al 2006) .
In a recent study, only one of 12 patients with in situ MCL developed clinically overt disease over a follow-up period of four years (Carvajal-Cuenca, et al 2012) . In view of the non- (Jares, et al 2012 , Saeow 2016 . The second type presents as a leukaemia with splenomegaly and lack of (or low volume) lymphadenopathy. It has highly mutated IGHV genes, a simple karyotype, kappa (rather than lambda) restriction and absent or low SOX11 expression (Fernandez, et al 2010 , Nodit, et al 2003 , Ondrejka, et al 2011 . It is associated with an indolent course although transformation may occur, which may be the first indication of a diagnosis of MCL (Kiel and Smith 2012) .
Genetics and molecular diagnostics
The characteristic cytogenetic abnormality of MCL is the t(11;14)(q13.3;q32.33) translocation, resulting in overexpression of cyclin D1 contributing to deregulated cell cycle progression at the G1-S phase boundary (Vandenberghe, et al 1991 , Williams, et al 1993 .
In practice, the translocation, which is usually detected by FISH on fresh or FFPE tissue , Reichard, et al 2006 , should be demonstrated in cases with atypical morphology, an aberrant immunophenotype, equivocal cyclin D1 positivity or unusual clinical presentation. Secondary cytogenetic abnormalities are common in MCL and the degree of karyotypic complexity is negatively associated with patient survival (Cuneo, et al 1999) (Katzenberger, et al 2008 , Parry-Jones, et al 2007 , Wlodarska, et al 1999 . The majority of MCL cases are characterised by an unmutated IGHV gene. A small proportion possess a highly mutated IGHV gene that is most commonly seen Author's final draft of a paper accepted for publication in British Journal of Haematology 2018 DOI 10.1111/bjh.15281.
in the indolent leukaemic group with low or absent expression of SOX11 (Nodit, et al 2003) .
A detailed account of the molecular pathogenesis of MCL can be found in several recent review articles (Campo and Rule 2015 , Dreyling, et al 2015 , Jares, et al 2012 , Vose 2013 ).
Biological prognostic factors
Many biological features have been examined such as growth pattern, blastoid morphology, TP53 expression, IGHV gene mutation status and secondary cytogenetic abnormalities with varying reports as to their significance (Argatoff, et al 1997 , Jares, et al 2012 , Katzenberger, et al 2006 , Nordstrom, et al 2014 , Norton, et al 1995 , Ott, et al 1997 . Identification of blastoid morphology may be difficult in view of variation in fixation and the subjective nature of assessing cell size. Proliferative activity by Ki67 index is the most important prognostic factor in routine diagnostic practice (Determann, et al 2008 , Katzenberger, et al 2006 , Tiemann, et al 2005 with an index of >30% associated with a poorer outcome.
Inter-observer variability in assessment of the proliferation index is well recognized. The European MCL Network suggest that counting the Ki67 positive cells among 100 lymphoma cells in each of two representative high-power fields generates improved consistency .
TP53 mutations predict a very poor outcome that appears not to be overcome by intensive up front therapy in younger patients (Eskelund, et al 2017) . In patients with true leukaemic (non-nodal) disease, SOX11 negativity can help predict an indolent phenotype but this does not apply in nodal disease. Kappa rather than lambda restriction may indicate indolent disease (see above). CD23 expression is also detected in this group by flow cytometry (Ondrejka, et al 2011) . None of these factors is currently robust enough to serve as a basis for modification of treatment.
Differential diagnosis
Cyclin D1 may be expressed in a number of other lymphoproliferative disorders, such as hairy cell leukaemia, multiple myeloma and 3% of DLBCL (Ehinger, et al 2008) . Adequate assessment of morphology and an appropriate panel of immunocytochemistry should prevent erroneous diagnosis. In the case of DLBCL, lack of a demonstrable IGH/CCND1 translocation and lack of immunoreactivity for SOX11 differentiates this group from pleomorphic variants of MCL (Hsiao, et al 2012) .
Recommendations
• Lymph node excision or adequate core biopsy is required for the diagnosis of nodal mantle cell lymphoma (MCL). In a non-nodal presentation, tissue biopsy or peripheral blood may provide the diagnosis.
• All cases should be subject to routine central review by an experienced haematopathologist.
• Immunohistochemical panels for the investigation of all B cell lymphomas should include cyclin D1.
• SOX11 immunostaining is required for the diagnosis of cyclin D1-negative MCL and should be included in panels where there is a suspicion of MCL.
• The presence of the t(11;14) translocation should be demonstrated by fluorescence in situ hybridization in cases with atypical morphology, aberrant immunophenotype, equivocal cyclin D1 positivity or unusual clinical presentation.
• It is recommended that the Ki67 Proliferation Index be recorded at baseline, with an index of > 30% suggestive of poorer outcome.
Initial Investigations, Staging and Prognostic Scores
Laboratory investigations:
Full blood count and blood film 
Imaging in MCL
Computed tomography (CT) of the neck, chest, abdomen and pelvis should be performed (contrast-enhanced unless contraindicated). Magnetic resonance imaging (MRI) may be useful for assessment of CNS disease where clinical suspicion is high (Ferrer, et al 2008 , Gill, et al 2009 , Gill and Seymour 2008 . ( 18 F) Fluorodeoxyglucose positron emission tomography (FDG-PET) is now used in the assessment of many types of lymphoma. It has been shown that MCL is FDG-avid, particularly the blastoid variant and nodal disease (Brepoels, et al 2008) . However, in contrast to other lymphomas, FDG-PET has been shown to have lower sensitivity in staging MCL, particularly extranodal disease and has not been shown to upstage compared with CT scan (Hosein, et al 2011) . Routine use of FDG-PET for Author's final draft of a paper accepted for publication in British Journal of Haematology 2018 DOI 10.1111 this purpose cannot currently be recommended outside the context of a clinical trial.
Although the role of FDG-PET in early stage MCL remains unproven, it may be considered if radical radiotherapy is being proposed.
Endoscopy -some authorities recommend routine colonoscopy and upper gastro-intestinal (GI) endoscopy as part of staging investigations in MCL (Zelenetz& Hoppe, 2001 ), on the basis that prospective studies have identified microscopic involvement by MCL of the GI tract in 92% of cases (Salar et al, 2006) . This finding rarely (less than 4% of cases) changes clinical management (Romaguera, et al 2003) . Endoscopy should be performed on the basis of clinical symptoms, particularly in those patients with features of GI bleeding or if clinical stage 1A disease is present and radiotherapy with curative intent is planned. Where endoscopy is performed, biopsies of any suspicious lesions, and also macroscopically normal areas, should be taken for histological examination.
Pregnancy testing in women of childbearing age prior to chemotherapy

Staging
The modified Ann Arbor staging system (Lister et al 1989) is used. As most patients with MCL have blood and bone marrow involvement at presentation, clinical stage in isolation is not of great prognostic significance.
Clinical prognostic scoring systems
The international prognostic index (IPI) is not reliable in MCL , Moller, et al 2006 . A prognostic scoring system specifically for MCL, the MCL international prognostic index (MIPI) has been devised . A simplification of this score 
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